However, in cancer types for which there was no correlation between CD8 T-cell levels and neoantigen levels, such as breast cancer, prostate cancer, and glioma, the ORR of immune checkpoint inhibitors in TMB-H tumors was 15.3% (95% CI 9.2–23.4; p = 0.95), which was significantly lower than in TMB-L tumors (OR: 0.46; 95% CI 0.24–0.88; p = 0.02) [36]. Here, CD8A is linked to cancer.